121 related articles for article (PubMed ID: 26436329)
1. Dasatinib-induced nephrotic syndrome.
Hirano T; Hashimoto M; Korogi Y; Tsuji T; Miyanaka K; Yamasaki H; Tsuda H
Leuk Lymphoma; 2016; 57(3):726-7. PubMed ID: 26436329
[No Abstract] [Full Text] [Related]
2. Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction.
Muller-Hansma AHG; van der Lugt J; Zwaan CM
Neth J Med; 2017 Dec; 75(10):428-431. PubMed ID: 29256412
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib-induced loss of eyebrows.
Naithani R
Br J Haematol; 2017 Nov; 179(3):362. PubMed ID: 28737227
[No Abstract] [Full Text] [Related]
4. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.
Ochiai S; Sato Y; Minakawa A; Fukuda A; Fujimoto S
BMC Nephrol; 2019 Mar; 20(1):87. PubMed ID: 30845905
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
Chang H; Hung YS; Chou WC
Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
[TBL] [Abstract][Full Text] [Related]
7. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
8. Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.
Ohta S; Najima Y; Imamura J
Br J Haematol; 2015 Jun; 169(5):612. PubMed ID: 25855138
[No Abstract] [Full Text] [Related]
9. [Dasatinib-related pneumonia? An example of pharmacovigilance survey].
Audemard A; de la Gastine B; Chantepie S; Verger H; Gac AC; Bergot E; Reman O
Rev Mal Respir; 2015 Jan; 32(1):84-6. PubMed ID: 25618211
[No Abstract] [Full Text] [Related]
10. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
11. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.
Ruebner RL; Copelovitch L; Evageliou NF; Denburg MR; Belasco JB; Kaplan BS
Pediatr Nephrol; 2014 May; 29(5):863-9. PubMed ID: 24310825
[TBL] [Abstract][Full Text] [Related]
12. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
13. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
[No Abstract] [Full Text] [Related]
14. Cytomegalovirus infection- and dasatinib-induced proteinuria in Ph+ALL.
Kawaguchi H; Tamura Y; Suzuki S; Asano-Murakoshi T; Nonoyama S
Pediatr Int; 2017 Jun; 59(6):740-741. PubMed ID: 28444835
[No Abstract] [Full Text] [Related]
15. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Shah NP; Wallis N; Farber HW; Mauro MJ; Wolf RA; Mattei D; Guha M; Rea D; Peacock A
Am J Hematol; 2015 Nov; 90(11):1060-4. PubMed ID: 26284693
[TBL] [Abstract][Full Text] [Related]
16. Coronary epicardic vasospasm in patient treated with desatinib for lymphoblastic leukaemia: the other side of the medal.
Scalone G; Mariani L; Aimi A; Grossi P
Eur Heart J; 2019 Apr; 40(15):1235. PubMed ID: 30759203
[No Abstract] [Full Text] [Related]
17. Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome.
Hirabayashi S; Hasegawa D; Yamamoto K; Nishimura A; Hosoya Y; Shuo T; Kiyokawa N; Miura M; Takahashi N; Manabe A
Pediatr Blood Cancer; 2019 May; 66(5):e27612. PubMed ID: 30663211
[No Abstract] [Full Text] [Related]
18. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
19. Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
Zheng FY; Lu AD; Zuo YX; Jia YP; Wu J; Zhang LP
Leuk Res; 2020 Aug; 95():106405. PubMed ID: 32590107
[TBL] [Abstract][Full Text] [Related]
20. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
